Introduction
The development of osteoporosis, and particularly vertebral collapse, is commonly regarded as a constant danger of long-term corticosteroid therapy. In some cases it may be the unfortunate price which has to be paid for control of such diseases as rheumatoid arthritis, nephritis, or asthma. The criteria which are used to define the presence of osteoporosis clearly affect the reported incidence of this complication of corticosteroid drugs. Studies which rely on the development of relatively late features of osteoporosis, such as loss of height or radiological evidence of vertebral collapse (McAllen, 1970) , may tend to underestimate the true incidence of bone disease. Conversely the use of x-ray densitometry (Cameron et al., 1968) detecting in practice ±4% changes in bone mineral content (Johnston et al., 1968) may suggest a much higher incidence of this complication of corticosteroid drugs (Bjelle and Nilsson, 1970; Mueller et al., 1970) .
The disadvantage of these densitometric techniques is that they rely on measurements made on limb bones though the peripheral and axial skeletons may not necessarily be symmetrically involved in osteoporosis (Nordin, 1971) . Measurement of total skeletal calcium might avoid difficulties in asymmetry of the osteoporotic process, and the present study discusses the application of in-vivo neutron activation analysis to this problem. The neutron activation technique (Anderson et al., 1964; Chamberlain et al., 1968; Palmer et al., 1968; Cohn et al., 1970) depends on the induction of the radioactive isotope 49Ca from stable 48Ca by in-vivo neutron bombardment. The induced radioactivity can be measured by external counting and provides an index of total body calcium. The method used in the present study (Chamberlain et al., 1970) makes it possible to measure sequential changes in total body calcium with an accuracy of ±4% . Since less than 1% of the calcium in the body lies outside bone such measurements represent, for practical purposes, changes in total skeletal calcium. Whole-body neutron activation analysis is more sensitive than conventional radiology and may provide useful, additional, and complementary information to that obtained by densitometric techniques.
The present study reports the results of sequential measurements of total body calcium using an in-vivo neutron activation analysis technique.
Patients and Methods
Five patients treated with long-term corticosteroid therapy were studied for periods of 20-33 months. During the study the underlying disease process was controlled by corticosteroid therapy in all of them. Admission to hospital was infrequent and all remained fully ambulant.
Corticosteroid dosage is shown in fig. 1 . Plain radiographs of the skeleton in cases 1-4 were normal throughout the study. There was, however, qualitative evidence of mild rarefaction of the thoracic and lumbar spine in case 5 in February 1970, but radiographs in October 1971 were considered to be normal. 
Discussion
The ability of the in-vivo, neutron activation technique to detect sequential changes-in total body calcium in metabolic bone disease has previously been described Hosking and Chamberlain, 1973) . In osteoporosis the mineralized bone mass per unit volume is reduced but the bone is in other respects normal (Nordin, 1971) . In these circumstances a decrease in total body calcium may be taken as a reasonable index of developing osteoporosis. The lack of change in total body calcium in the first four patients treated with corticosteroids suggests, therefore, that if osteoporosis has developed during the course of the study then this represents a loss of less than 4% of the total skeletal calcium.
In some of the earlier reports of osteoporosis occurring during corticosteroid treatment (Demartini et al., 1952; Curtiss et al., 1954; Reifenstein, 1958) (Soffer and Bader, 1952) . Nor was there evidence of osteoporosis in a group with corticosteroid-treated allergic (Klein et al., 1965) (Holloway, 1970) . Though there was a considerable change in weight during the study there was no reduction of fat fold thickness (Fletcher, 1962) of this order of magnitude. In fact no change in total body calcium was detected during the first six months of study when weight loss was most pronounced. It is unlikely, therefore, that the measured changes in total body calcium were attributed to alteration in body habitus. A second factor which may be relevant is the improved control of hepatocellular damage which was achieved in the last year of study ( fig. 2 ). Osteoporosis may occur in chronic liver disease (Paterson and Losowsky, 1967) of comparable severity to the present case. Osteomalacia has not been excluded in this case by means of bone biopsy, but in the absence of biliary cirrhosis or obstruction it is probably uncommon. However, the improvement in liver function which occurred during the period of study hardly seems to be of sufficient magnitude to account for such a noticeable change in total body calcium. Such a rise implies reversal of a previous phase of oesteoporosis, though this type of bone disease is generally thought to be irreversible (Rose, 1967) .
Alternative'y it may be that the increased well-being and improved liver function as a result of corticosteroid treatment led to increased ambulation and reversal of the osteoporosis of immobilization. In support of this view is the report by Donaldson et al. (1970) who used y-ray transmission scanning of the os calcis during immobilization. The loss of bone mineral which occurred to a greater extent in the weightbearing bones than in the remainder of the skeleton appeared to be reversible after ambulation. Similar evidence of an increase in bone mineral content in response to physical activity was also found by Smith (1971) using a y-ray densitometry study of the midshaft of radius. It may be that in the treatment of severe diseases with corticosteroid drugs any tendency to produce osteoporosis may be more than compensated by the return of well-being and mobility produced by this form of therapy. 1965 '196'1967 '1969 ' 1971 . Corticosteroid dosage, liver function, and changes in total body calcium.
